This content is from: Patents
Analysis: Complexity lies ahead for CRISPR patents after PTAB decision
The eagerly-anticipated ruling from the PTAB of “no interference-in-fact” is a win for the Broad Institute in its CRISPR patent battle with University of California Berkeley. But much wrangling lies ahead over the rights to the gene-editing technology, including a potential appeal and likely licensing disputes
To access our in-house intelligence please request a trial here.
Read this article – and more – for a one-week period.
REQUEST ACCESSAre you already an Managing IP subscriber? Login here